Catalio Capital Management just dropped £20 million, about $20 million, into Amalgam Rx, Inc., and if you think this is just another credit facility, you’re missing the signal in the noise. This Wilmington, Delaware crew isn’t slinging another health app with a shiny interface. They’ve built a modular, FDA-cleared, CE-marked Software-as-a-Medical-Device platform that sits inside electronic health record systems and feeds providers medical-grade AI insights exactly when and where care happens. It’s not about making the workflow prettier; it’s about making the decisions inside it smarter.
Founded in 2016 by Ryan Sysko and Dr. Suzanne Clough, MD, Amalgam Rx came out of more than two decades of digital therapeutics and chronic care innovation. Their goal was deceptively simple: unify payers, providers, and life sciences so that patient care stops being a disconnected relay race and starts being a data-driven, point-of-care collaboration. Seven years later, they’re serving nearly 10 million patients, powering over 70 million clinical decisions, and working with partners like Aetna, Novo Nordisk, and AWS for Health. Numbers don’t lie, and these ones are loud.
Catalio isn’t just wiring the money and disappearing. With the first $12 million already drawn, Amalgam Rx is refinancing debt for flexibility, scaling deployments, and tapping into Catalio’s advisory bench of 45+ venture partners. That’s not passive capital; that’s fuel and navigation rolled into one. And when your clients span four continents and your AI is already embedded in the clinical bloodstream, speed and precision matter as much as the cash.
The leadership bench is stacked for it. President Chris Bergstrom brings the BCG polish and digital therapeutics track record. CTO Matti Prasad is building integrations with insulin delivery devices and continuous glucose monitors that make the hardware/software handshake seamless. Chief Data Scientist Bharath Sudharsan is shepherding billions of real-world data points into algorithms that can pass regulatory, ethical, and clinical sniff tests. This is not a team guessing their way through scaling; this is a unit executing with intent.
Catalio’s bet is a read on where healthcare is headed: AI that doesn’t just assist, but integrates, regulates, and scales without losing clinical integrity. For life sciences companies looking to deliver outcomes, for payers trying to keep populations healthy without burning cash, and for providers who just want decision support they can trust, Amalgam Rx is about to make the next move very hard to ignore.
